HUP0300235A2 - Heterociklikus oldalláncot tartalmazó, N-szubsztituált metalloproteáz inhibitorok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk - Google Patents
Heterociklikus oldalláncot tartalmazó, N-szubsztituált metalloproteáz inhibitorok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásukInfo
- Publication number
- HUP0300235A2 HUP0300235A2 HU0300235A HUP0300235A HUP0300235A2 HU P0300235 A2 HUP0300235 A2 HU P0300235A2 HU 0300235 A HU0300235 A HU 0300235A HU P0300235 A HUP0300235 A HU P0300235A HU P0300235 A2 HUP0300235 A2 HU P0300235A2
- Authority
- HU
- Hungary
- Prior art keywords
- group
- atom
- heterocyclic
- aliphatic
- aromatic
- Prior art date
Links
- 125000000623 heterocyclic group Chemical group 0.000 title abstract 4
- 239000003475 metalloproteinase inhibitor Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000001931 aliphatic group Chemical group 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 125000001183 hydrocarbyl group Chemical group 0.000 abstract 3
- 125000005343 heterocyclic alkyl group Chemical group 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 125000004434 sulfur atom Chemical group 0.000 abstract 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical group ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 abstract 1
- 101000998548 Yersinia ruckeri Alkaline proteinase inhibitor Proteins 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- 125000000751 azo group Chemical group [*]N=N[*] 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- -1 carboxy, sulfonyl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 150000003949 imides Chemical class 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
- C07D211/66—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having a hetero atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D309/06—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Pyrane Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A találmány tárgyát általános képletű metalloproteáz inhibitorvegyületek -ahol R1 hidroxicsoport és hidroxil-amidcsoport; R2hidrogénatom, alifás, aromás, heterociklusos szénhidrogéncsoport éshalogénatom; R3 alifás, aromás, heterociklusos szénhidrogéncsoport; n = 0-4 közötti egész szám; A monociklikus heterociklusosalkilcsoport; E kovalens kötés, alkil-, karbonil-, karboxi-,szulfonilcsoport; X hidrogénatom, alifás, aromás, heterociklusos szénhidrogéncsoport; G kénatom, oxigénatom, -N(R5)-, - C(R5)=C(R5')-, -N=C(R5)-általános képletű csoport és azocsoport; G' kénatom, oxigénatom, -N(R6) -, -C (R6)=C (R6') -, -N=C (R6) - általános képletű csoport ésazocsoport; M -CH= képletű csoport és nitrogénatom; Z cikloalkil- ésheterociklusos alkilcsoport vagy optikai izomereik, diasztereomereik,enantiomereik, gyógyászatilag elfogadható sóik vagy biológiailaghidrolizálható amidjaik, észtereik vagy imidjeik, ezeket tartalmazógyógyszerkészítmények és előállításuk képezik. Ó
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19130200P | 2000-03-21 | 2000-03-21 | |
PCT/US2001/008931 WO2001070691A1 (en) | 2000-03-21 | 2001-03-02 | Heterocyclic side chain containing, n-substituted metalloprotease inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
HUP0300235A2 true HUP0300235A2 (hu) | 2003-08-28 |
Family
ID=22704936
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0300235A HUP0300235A2 (hu) | 2000-03-21 | 2001-03-02 | Heterociklikus oldalláncot tartalmazó, N-szubsztituált metalloproteáz inhibitorok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk |
Country Status (22)
Country | Link |
---|---|
US (2) | US6949545B2 (hu) |
EP (1) | EP1265864A1 (hu) |
JP (1) | JP2003528080A (hu) |
KR (1) | KR20020081465A (hu) |
CN (1) | CN1425004A (hu) |
AR (1) | AR030197A1 (hu) |
AU (1) | AU2001245891A1 (hu) |
BR (1) | BR0109328A (hu) |
CA (1) | CA2404131A1 (hu) |
CZ (1) | CZ20023145A3 (hu) |
HU (1) | HUP0300235A2 (hu) |
IL (1) | IL151125A0 (hu) |
MA (1) | MA26884A1 (hu) |
MX (1) | MXPA02009311A (hu) |
NO (1) | NO20024520D0 (hu) |
NZ (1) | NZ520657A (hu) |
PE (1) | PE20011137A1 (hu) |
PL (1) | PL365444A1 (hu) |
RU (1) | RU2245876C2 (hu) |
SK (1) | SK12842002A3 (hu) |
WO (1) | WO2001070691A1 (hu) |
ZA (1) | ZA200206298B (hu) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2304989T3 (es) * | 1999-12-28 | 2008-11-01 | Teikoku Seiyaku Co., Ltd. | Agente antiprurigonoso para uso externo. |
EP1265863A1 (en) * | 2000-03-21 | 2002-12-18 | The Procter & Gamble Company | Heterocyclic side chain containing metalloprotease inhibitors |
DE60236350D1 (de) * | 2001-03-14 | 2010-06-24 | Novartis Ag | Azacycloalkyl-substituierte essigsäure-derivate zur verwendung als mmp-inhibitoren |
US20070160655A1 (en) * | 2003-04-23 | 2007-07-12 | Sefton Michael V | Hydroxyamate-containing materials for the inhibition of matrix metalloproteinases |
US20040213758A1 (en) * | 2003-04-23 | 2004-10-28 | Rimon Therapeutics Ltd. | Hydroxyamate-containing materials for the inhibition of matrix metalloproteinases |
US7576222B2 (en) | 2004-12-28 | 2009-08-18 | Wyeth | Alkynyl-containing tryptophan derivative inhibitors of TACE/matrix metalloproteinase |
KR100717022B1 (ko) * | 2005-08-27 | 2007-05-10 | 삼성전자주식회사 | 잉크젯 프린트헤드 및 그 제조방법 |
NZ601350A (en) * | 2007-11-16 | 2013-08-30 | Abbvie Inc | Method of treating arthritis |
US8557983B2 (en) | 2008-12-04 | 2013-10-15 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
US20100160322A1 (en) | 2008-12-04 | 2010-06-24 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
UA108193C2 (uk) * | 2008-12-04 | 2015-04-10 | Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань | |
US8563735B2 (en) | 2008-12-05 | 2013-10-22 | Abbvie Inc. | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
US8586754B2 (en) | 2008-12-05 | 2013-11-19 | Abbvie Inc. | BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
EP2376480B1 (en) * | 2008-12-05 | 2016-06-01 | AbbVie Inc. | Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
US20100319773A1 (en) * | 2009-06-22 | 2010-12-23 | Solarmation, Inc. | Optics for Concentrated Photovoltaic Cell |
Family Cites Families (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4743587A (en) | 1985-09-10 | 1988-05-10 | G. D. Searle & Co. | Hydroxamic acid based collagenase inhibitors |
US4771038A (en) | 1986-01-21 | 1988-09-13 | Ici Americas Inc. | Hydroxamic acids |
DK77487A (da) | 1986-03-11 | 1987-09-12 | Hoffmann La Roche | Hydroxylaminderivater |
ZW23187A1 (en) | 1986-12-15 | 1988-06-29 | Hoffmann La Roche | Phosphinic acid derivatives |
US5183900A (en) | 1990-11-21 | 1993-02-02 | Galardy Richard E | Matrix metalloprotease inhibitors |
US5892112A (en) | 1990-11-21 | 1999-04-06 | Glycomed Incorporated | Process for preparing synthetic matrix metalloprotease inhibitors |
GB9102635D0 (en) | 1991-02-07 | 1991-03-27 | British Bio Technology | Compounds |
GB9107368D0 (en) | 1991-04-08 | 1991-05-22 | Smithkline Beecham Plc | Novel compounds |
WO1992022523A2 (en) | 1991-06-14 | 1992-12-23 | Research Corporation Technologies, Inc. | Peptide derivatives of collagenase inhibitor |
JPH05125029A (ja) | 1991-11-06 | 1993-05-21 | Yamanouchi Pharmaceut Co Ltd | 新規なアミド化合物又はその塩 |
EP0623143A1 (en) | 1992-01-15 | 1994-11-09 | Merck & Co. Inc. | Substituted phosphinic acid-containing peptidyl derivatives as antidegenerative agents |
AU4267293A (en) | 1992-05-01 | 1993-11-29 | British Biotech Pharmaceuticals Limited | Use of MMP inhibitors |
US5318964A (en) | 1992-06-11 | 1994-06-07 | Hoffmann-La Roche Inc. | Hydroxamic derivatives and pharmaceutical compositions |
AU666727B2 (en) | 1992-06-25 | 1996-02-22 | F. Hoffmann-La Roche Ag | Hydroxamic acid derivatives |
US5326760A (en) | 1992-06-29 | 1994-07-05 | Glaxo, Inc. | Aminobutanoic acid compounds having metalloprotease inhibiting properties |
GB9215665D0 (en) | 1992-07-23 | 1992-09-09 | British Bio Technology | Compounds |
GB9223904D0 (en) | 1992-11-13 | 1993-01-06 | British Bio Technology | Inhibition of cytokine production |
US5646167A (en) | 1993-01-06 | 1997-07-08 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamix acids |
US5455258A (en) * | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
US5506242A (en) | 1993-01-06 | 1996-04-09 | Ciba-Geigy Corporation | Arylsufonamido-substituted hydroxamic acids |
GB9308695D0 (en) | 1993-04-27 | 1993-06-09 | Celltech Ltd | Peptidyl derivatives |
DE69419473T2 (de) | 1993-04-27 | 2000-03-16 | Celltech Therapeutics Ltd | Peptidylderivate als inhibitoren von metalloproteinase |
WO1995004033A1 (en) | 1993-08-02 | 1995-02-09 | Celltech Limited | Succinamide derivatives, processes for their preparation and their use as gelatinase and collagenase inhibitors |
US5545735A (en) | 1993-10-04 | 1996-08-13 | Merck & Co., Inc. | Benzo-Fused Lactams promote release of growth hormone |
US5470834A (en) | 1993-10-06 | 1995-11-28 | Florida State University | Sulfoximine and suldodiimine matrix metalloproteinase inhibitors |
US5403952A (en) | 1993-10-08 | 1995-04-04 | Merck & Co., Inc. | Substituted cyclic derivatives as novel antidegenerative agents |
UA48121C2 (uk) | 1993-11-04 | 2002-08-15 | Сінтекс (С.Ш.А.) Інк. | Інгібітори матричних металопротеаз і фармацетична композиція на їх основі |
GB9323165D0 (en) | 1993-11-10 | 1994-01-05 | Chiros Ltd | Compounds |
DK0822186T3 (da) | 1994-01-20 | 2000-06-26 | British Biotech Pharm | L-tert-leucin-2-pyridylamid |
GB9401129D0 (en) | 1994-01-21 | 1994-03-16 | British Bio Technology | Hydroxamic acid derivatives as metalloproteinase inhibitors |
JP3827324B2 (ja) | 1994-01-22 | 2006-09-27 | ブリテッシュ バイオテック ファーマシューティカルズ リミテッド | 金属タンパク質分解酵素阻害剤 |
US5514716A (en) | 1994-02-25 | 1996-05-07 | Sterling Winthrop, Inc. | Hydroxamic acid and carboxylic acid derivatives, process for their preparation and use thereof |
US5665753A (en) | 1994-03-03 | 1997-09-09 | Smithkline Beecham Corporation | Cytokine inhibiting imidazole substituted hydroxamic acid derivatives |
GB9405076D0 (en) | 1994-03-16 | 1994-04-27 | Inst Of Ophtalmology | A medical use of matrix metalloproteinase inhibitors |
DE4411311A1 (de) * | 1994-03-31 | 1995-10-05 | Basf Ag | Verfahren zur Herstellung von lagerstabilen wäßrigen Lösungen von Vinylamin-Einheiten enthaltenden Polymerisaten |
GB9501737D0 (en) | 1994-04-25 | 1995-03-22 | Hoffmann La Roche | Hydroxamic acid derivatives |
WO1995029892A1 (en) | 1994-04-28 | 1995-11-09 | The Du Pont Merck Pharmaceutical Company | Hydroxamic acid and amino acid derivatives and their use as anti-arthritic agents |
JPH07304770A (ja) | 1994-05-11 | 1995-11-21 | Kanebo Ltd | 新規ベンゾアゼピノン誘導体 |
ATE181055T1 (de) | 1994-05-28 | 1999-06-15 | British Biotech Pharm | Succinyl hydroxamsäure-, n-formyl-n-hydroxy- aminocarbonsäure- und succinsäureamid-derivate und ihre verwendung als metalloprotease- inhibitoren |
GB9411088D0 (en) | 1994-06-03 | 1994-07-27 | Hoffmann La Roche | Hydroxylamine derivatives |
GB9411598D0 (en) | 1994-06-09 | 1994-08-03 | Hoffmann La Roche | Hydroxamic acid derivatives |
GB9412350D0 (en) | 1994-06-20 | 1994-08-10 | Fujisawa Pharmaceutical Co | New compound and its preparation |
NZ288298A (en) | 1994-06-22 | 1998-12-23 | British Biotech Pharm | Hydroxamic acid and carboxylic acid derivatives; medicaments containing such derivatives that are metalloproteinase inhibitors |
GB9416897D0 (en) | 1994-08-20 | 1994-10-12 | British Biotech Pharm | Metalloproteinase inhibitors |
AR002945A1 (es) | 1994-11-15 | 1998-05-27 | Bayer Corp | Acidos 4-biarilbutirico o 5-biarilpentanoico sustituidos y sus derivados como inhibidores de las metaloproteasas de matriz, composicion que los contiene, y metodos para la preparacion de dichos compuestos |
US5919940A (en) | 1995-01-20 | 1999-07-06 | British Biotech Pharmaceuticals Limited | Metalloproteinase inhibitors |
US5573438A (en) * | 1995-04-25 | 1996-11-12 | D'andrea; Deborah | Book including candy as a part of the pages |
US5886022A (en) | 1995-06-05 | 1999-03-23 | Bayer Corporation | Substituted cycloalkanecarboxylic acid derivatives as matrix metalloprotease inhibitors |
US6124333A (en) | 1995-06-22 | 2000-09-26 | British Biotech Pharmaceuticals Limited | Metalloproteinase inhibitors |
TW453995B (en) | 1995-12-15 | 2001-09-11 | Novartis Ag | Certain alpha-substituted arylsulfonamido acetohydroxamic acids |
JP3628335B2 (ja) * | 1996-01-23 | 2005-03-09 | 塩野義製薬株式会社 | スルホン化されたアミノ酸誘導体およびそれを含有するメタロプロティナーゼ阻害剤 |
EP0927156A1 (en) | 1996-09-04 | 1999-07-07 | Warner-Lambert Company | Biphenyl butyric acids and their derivatives as inhibitors of matrix metalloproteinases |
EA002594B1 (ru) | 1997-02-03 | 2002-06-27 | Пфайзер Продактс Инк. | Производные арилсульфониламиногидроксамовой кислоты |
PT983267E (pt) * | 1997-03-04 | 2005-06-30 | Pharmacia Corp | Compostos sulfonamida amidoaromaticas de acido hidroxamico |
DE19719621A1 (de) * | 1997-05-09 | 1998-11-12 | Hoechst Ag | Sulfonylaminocarbonsäuren |
NZ503945A (en) * | 1997-07-31 | 2002-11-26 | Procter & Gamble | Metalloprotease-inhibiting amide derivatives |
DK0895988T3 (da) * | 1997-08-08 | 2002-09-09 | Pfizer Prod Inc | Arylsulfonylaminohydroxamsyrederivater |
WO1999018079A1 (en) | 1997-10-06 | 1999-04-15 | Warner-Lambert Company | Heteroaryl butyric acids and their derivatives as inhibitors of matrix metalloproteinases |
HUP0101176A3 (en) | 1998-02-04 | 2002-06-28 | Novartis Ag | Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases, process for their preparation and pharmaceutical compositions containing them |
PA8469501A1 (es) * | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico |
FR2782080B1 (fr) * | 1998-08-10 | 2001-01-05 | Adir | Nouveaux derives d'acide hydroxamique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
US6677360B2 (en) * | 1998-12-16 | 2004-01-13 | Bayer Aktiengesellschaft | Biphenyl and biphenyl-analogous compounds as integrin antagonists |
US6225311B1 (en) | 1999-01-27 | 2001-05-01 | American Cyanamid Company | Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors |
MXPA01008857A (es) | 1999-03-03 | 2002-07-02 | Procter & Gamble | Inhibidores de metaloproteasa dihetero sustituidos. |
CA2375524C (en) | 1999-05-28 | 2006-11-28 | Lawrence Alan Reiter | 3-(arylsulfonylamino)-tetrahydropyran-3-carboxylic acid hydroxamides |
HN2000000052A (es) | 1999-05-28 | 2001-02-02 | Pfizer Prod Inc | Hidroxiamidas de acidos 3- (arilsulfonilamino)- tetrahidrofuran-3-carboxilicos. |
US6696456B1 (en) * | 1999-10-14 | 2004-02-24 | The Procter & Gamble Company | Beta disubstituted metalloprotease inhibitors |
PE20020291A1 (es) * | 2000-08-21 | 2002-04-17 | Hoffmann La Roche | Profarmacos para ligandos del receptor nmda |
-
2001
- 2001-03-02 RU RU2002128007/04A patent/RU2245876C2/ru not_active IP Right Cessation
- 2001-03-02 MX MXPA02009311A patent/MXPA02009311A/es unknown
- 2001-03-02 BR BR0109328-2A patent/BR0109328A/pt not_active IP Right Cessation
- 2001-03-02 AU AU2001245891A patent/AU2001245891A1/en not_active Abandoned
- 2001-03-02 SK SK1284-2002A patent/SK12842002A3/sk unknown
- 2001-03-02 PL PL01365444A patent/PL365444A1/xx not_active Application Discontinuation
- 2001-03-02 EP EP01918867A patent/EP1265864A1/en not_active Withdrawn
- 2001-03-02 HU HU0300235A patent/HUP0300235A2/hu unknown
- 2001-03-02 IL IL15112501A patent/IL151125A0/xx unknown
- 2001-03-02 CZ CZ20023145A patent/CZ20023145A3/cs unknown
- 2001-03-02 KR KR1020027012313A patent/KR20020081465A/ko not_active Application Discontinuation
- 2001-03-02 CA CA002404131A patent/CA2404131A1/en not_active Abandoned
- 2001-03-02 JP JP2001568903A patent/JP2003528080A/ja not_active Withdrawn
- 2001-03-02 CN CN01806655A patent/CN1425004A/zh active Pending
- 2001-03-02 WO PCT/US2001/008931 patent/WO2001070691A1/en not_active Application Discontinuation
- 2001-03-02 NZ NZ520657A patent/NZ520657A/en unknown
- 2001-03-20 AR ARP010101310A patent/AR030197A1/es not_active Application Discontinuation
- 2001-03-21 PE PE2001000265A patent/PE20011137A1/es not_active Application Discontinuation
-
2002
- 2002-08-07 ZA ZA200206298A patent/ZA200206298B/en unknown
- 2002-09-13 US US10/243,511 patent/US6949545B2/en not_active Expired - Fee Related
- 2002-09-16 MA MA26819A patent/MA26884A1/fr unknown
- 2002-09-20 NO NO20024520A patent/NO20024520D0/no not_active Application Discontinuation
-
2004
- 2004-01-16 US US10/758,791 patent/US20040127498A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
SK12842002A3 (sk) | 2003-02-04 |
NZ520657A (en) | 2004-11-26 |
US20040127498A1 (en) | 2004-07-01 |
IL151125A0 (en) | 2003-04-10 |
CA2404131A1 (en) | 2001-09-27 |
WO2001070691A1 (en) | 2001-09-27 |
EP1265864A1 (en) | 2002-12-18 |
MXPA02009311A (es) | 2003-03-12 |
CZ20023145A3 (cs) | 2003-01-15 |
AU2001245891A1 (en) | 2001-10-03 |
BR0109328A (pt) | 2003-06-10 |
PL365444A1 (en) | 2005-01-10 |
JP2003528080A (ja) | 2003-09-24 |
KR20020081465A (ko) | 2002-10-26 |
PE20011137A1 (es) | 2001-12-04 |
NO20024520L (no) | 2002-09-20 |
RU2002128007A (ru) | 2004-02-27 |
CN1425004A (zh) | 2003-06-18 |
MA26884A1 (fr) | 2004-12-20 |
RU2245876C2 (ru) | 2005-02-10 |
NO20024520D0 (no) | 2002-09-20 |
AR030197A1 (es) | 2003-08-13 |
US20030139414A1 (en) | 2003-07-24 |
ZA200206298B (en) | 2003-04-11 |
US6949545B2 (en) | 2005-09-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0300262A2 (hu) | Heterociklusos oldalláncot tartalmazó metalloproteáz inhibitorok | |
HUP0300235A2 (hu) | Heterociklikus oldalláncot tartalmazó, N-szubsztituált metalloproteáz inhibitorok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
HUP9903916A2 (hu) | Foszfinsavamidok és ezeket tartalmazó gyógyszerkészítmények | |
PT1280797E (pt) | Inibidores da peptidase iv de dipeptidilo | |
HUP0201088A2 (hu) | Új alfa-aminosav-szulfonil-vegyületek, eljárás előállításukra és ilyen vegyületeket tartalmazó gyógyászati készítmények | |
HUP0000130A2 (hu) | 1,3-Heterociklusos fémproteáz inhibitorok | |
GEP20074148B (en) | Pyrrolo-triazine aniline compounds useful as kinase inhibitors | |
DE60022328D1 (de) | Amid-derivate | |
RS20050432A (en) | Novel aromatic fluoroglycoside derivatives,pharmaceutical products containing said compounds and the use thereof | |
RS20050394A (en) | Novel aromatic fluoroglycoside derivatives, pharmaceutical products containing said compounds and the use thereof | |
HUP0004595A2 (hu) | Aciklikus metalloproteáz inhibitorok | |
TW200800938A (en) | Indole carboxylic acid derivatives exhibiting PGD2 receptor antagonism | |
AP2003002841A0 (en) | Quinazolines as MMP-13 inhibitors | |
AR037460A1 (es) | Compuesto de hidroxietileno, composicion farmaceutica que lo comprende, uso del mismo para la fabricacion de un medicamento y procedimiento para su preparacion | |
ATE202076T1 (de) | Ester der 5-aminolevulinsäure als mittel zur photosensibilisierung in der chemotherapie | |
RS20050046A (en) | 3-z-/1-(4-(n-((4-methyl-piperazin-1-yl)- methylcarbonyl)-n- methyl-amino)- anilino)-1-phenyl-methylene/-6- methoxycarbonyl -2-indolinone- monoethanesulphonate and the use thereof as a pharmaceutical composition | |
PT1263730E (pt) | Derivados amina para o tratamento de apoptose | |
MXPA00006605A (es) | Compuestos de carbonil-indol biciclicos como agentes antiinflamatorios/analgesicos. | |
HUP0202876A2 (hu) | Karboxipeptidáz U gátló új vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
HUP0203054A2 (hu) | Farnezil protein transzferáz inhibitorok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
DZ1694A1 (fr) | "n-(2-Aminoethyl)-benzothialozones". | |
GEP20053626B (en) | Substituted 8-Arylquinoline Phosphodiesterase-4 Inhibitors, Pharmaceutical Composition Containing Them and Use Thereof | |
HUP0102981A2 (hu) | Pirrolo[1,2-a]pirazin-származékok és ezeket tartalmazó gyógyszerkészítmények | |
HUP0303204A2 (hu) | 1-Metilkarbapenem-származékok és ezeket tartalmazó gyógyszerkészítmények | |
HUP0203275A2 (hu) | 1-(Gyűrűs amino)-alkilciklohexán-származékok, ezeket tartalmazó görcsoldó hatású gyógyszerkészítmények, valamint ezek alkalmazása |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD9A | Lapse of provisional protection due to non-payment of fees |